Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Small Molecules
Filter     Order     Display # 
Date Item Title Hits
10 Mar 2010 Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche 25
10 Mar 2010 Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia 28
10 Mar 2010 Limerick BioPharma Announces Positive Phase 1a Data for LIM-0705 24
10 Mar 2010 Cempra Announces the Completion of Phase 1 Studies for CEM-101, a Next-Generation Macrolide 24
10 Mar 2010 BioAlliance Announces Positive Preliminary Results in the First Phase I Clinical Trial of fentanyl Lauriad 22
09 Mar 2010 INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 40
09 Mar 2010 Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease 37
09 Mar 2010 Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53) 52
09 Mar 2010 FDA Advisory Committee Recommends Approval of InterMune's Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis 32
09 Mar 2010 Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction 35
09 Mar 2010 Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 27
09 Mar 2010 Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury 20
09 Mar 2010 Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies 22
09 Mar 2010 Omeros Licenses PDE7 Compounds for Parkinson's Disease Program 27
08 Mar 2010 Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute for Development of Further Next-Generation Class II-Selective HDAC Inhibitor Compounds 5
08 Mar 2010 NeuroSearch announces new findings from the MermaiHD Phase III study supporting potential disease modifying properties of Huntexil 39
08 Mar 2010 RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer 41
08 Mar 2010 Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer 42
08 Mar 2010 Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU 41
08 Mar 2010 Harbor BioSciences Reports New Phase I/IIa Data at ASCO Symposium and Announces Plans to Advance Prostate Cancer Treatment Apoptone to Phase IIb 36
08 Mar 2010 Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of a Clinical Study Assessing Relative Abuse Potential 30
05 Mar 2010 ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior to Enoxaparin in the Prevention of Venous Thromboembolism Following Knee Replacement Surgery 63
05 Mar 2010 Phase III REGION-I Study Shows PEP005 (ingenol mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions in Patients with Actinic Keratosis 102
05 Mar 2010 Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 48
04 Mar 2010 Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer 61
03 Mar 2010 Rexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol to FDA 44
03 Mar 2010 Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 82
03 Mar 2010 PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY 59
03 Mar 2010 Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program 78
03 Mar 2010 Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine 70
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 8101

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics